{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:41:35Z","timestamp":1716306095097},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,2,8]],"date-time":"2009-02-08T00:00:00Z","timestamp":1234051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s11940-009-0010-z","type":"journal-article","created":{"date-parts":[[2009,2,7]],"date-time":"2009-02-07T10:32:01Z","timestamp":1234002721000},"page":"77-84","source":"Crossref","is-referenced-by-count":6,"title":["Lambert-eaton myasthenic syndrome"],"prefix":"10.1007","volume":"11","author":[{"given":"Maria B.","family":"Weimer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,8]]},"reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(53)91358-0","volume":"265","author":"H.J. Anderson","year":"1953","unstructured":"Anderson HJ, Churchill-Davidson HC, Richardson AT: Bronchial neoplasm with myasthenia; prolonged apnoea after administration of succinylcholine. Lancet 1953, 265:1291\u20131293.","journal-title":"Lancet"},{"key":"10_CR2","first-page":"612","volume":"187","author":"E.H. Lambert","year":"1956","unstructured":"Lambert EH, Eaton LM, Rooke ED: Defect of neuromuscular conduction associated with malignant neoplasms [abstract]. Am J Physiol 1956, 187:612\u2013613.","journal-title":"Am J Physiol"},{"key":"10_CR3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1212\/WNL.29.5.720","volume":"29","author":"A.E. Rubenstein","year":"1979","unstructured":"Rubenstein AE, Horowitz SH, Bender AN: Cholinergic dysautonomia and Eaton-Lambert syndrome. Neurology 1979, 29:720\u2013723.","journal-title":"Neurology"},{"key":"10_CR4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","volume":"111","author":"J.H. O\u2019Neill","year":"1988","unstructured":"O\u2019Neill JH, Murray NMF, Newsom-Davis J: The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 1988, 111:577\u2013596.","journal-title":"Brain"},{"key":"10_CR5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/mus.880180707","volume":"18","author":"Z. Argov","year":"1995","unstructured":"Argov Z, Shapira Y, Averbuch-Heller L, Wirguin I: Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle Nerve 1995, 18:715\u2013719.","journal-title":"Muscle Nerve"},{"key":"10_CR6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0002-9343(72)90179-9","volume":"53","author":"L. Gutmann","year":"1972","unstructured":"Gutmann L, Crosby TW, Takamori M, Martin JD: The Eaton-Lambert syndrome and autoimmune disorders. Am J Med 1972, 53:354\u2013356.","journal-title":"Am J Med"},{"key":"10_CR7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0303-8467(02)00054-9","volume":"104","author":"P.W. Wirtz","year":"2002","unstructured":"Wirtz PW, Smallegange TM, Wintzen AR, Verchuuren JJ: Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg 2002, 104:359\u2013363.","journal-title":"Clin Neurol Neurosurg"},{"key":"10_CR8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00415-004-0528-7","volume":"251","author":"P.W. Wirtz","year":"2004","unstructured":"Wirtz PW, Bradshaw J, Wintzen AR, Verchuuren JJ: Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol 2004, 251:1255\u20131259.","journal-title":"J Neurol"},{"key":"10_CR9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1126\/science.2447652","volume":"239","author":"Y.I. Kim","year":"1988","unstructured":"Kim YI, Neher E: IgG from patients with Lambert-Eaton syndrome blocks voltage-dependent calcium channels. Science 1988, 239:405\u2013409.","journal-title":"Science"},{"key":"10_CR10","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","volume":"332","author":"V.A. Lennon","year":"1995","unstructured":"Lennon VA, Kryzer TJ, Griesmann GE, et al.: Calciumchannel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995, 332:1467\u20131474.","journal-title":"N Engl J Med"},{"key":"10_CR11","first-page":"21","volume-title":"Nerve Conduction Studies","author":"S.J. Oh","year":"1993","unstructured":"Oh SJ: Clinical electromyography. In Nerve Conduction Studies, edn 2. Baltimore: Williams & Wilkins; 1993:21\u201323.","edition":"edn 2"},{"key":"10_CR12","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/mus.1140","volume":"24","author":"AAEM Quality Assurance Committee","year":"2001","unstructured":"AAEM Quality Assurance Committee: Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 2001, 24:1239\u20131257.","journal-title":"Muscle Nerve"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ana.410070112","volume":"7","author":"R.J. Hawley","year":"1980","unstructured":"Hawley RJ, Cohen MH, Saini N, Armbrustmacher VW: The carcinomatous neuromyopathy of oat cell lung cancer. Ann Neurol 1980, 7:65\u201372.","journal-title":"Ann Neurol"},{"key":"10_CR14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jneuroim.2004.10.018","volume":"159","author":"P.W. Wirtz","year":"2005","unstructured":"Wirtz PW, Wilcox N, van der Slik AR, et al.: HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 2005, 159:230\u2013237.","journal-title":"J Neuroimmunol"},{"key":"10_CR15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1196\/annals.1254.065","volume":"998","author":"D.B. Sanders","year":"2003","unstructured":"Sanders DB: Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann NY Acad Sci 2003, 998:500\u2013508.","journal-title":"Ann NY Acad Sci"},{"key":"10_CR16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1212\/01.WNL.0000129983.06983.4E","volume":"63","author":"R. Linke","year":"2004","unstructured":"Linke R, Schroeder M, Helmberger T, Voltz R: Antibodypositive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004, 63:282\u2013286.","journal-title":"Neurology"},{"key":"10_CR17","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14656566.7.10.1323","volume":"7","author":"J.J. Verschuuren","year":"2006","unstructured":"Verschuuren JJ, Wirtz PW, Titulaer MJ, et al.: Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin Pharmacother 2006, 7:1323\u20131336.","journal-title":"Expert Opin Pharmacother"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.40.10.1552","volume":"40","author":"C.H. Chalk","year":"1990","unstructured":"Chalk CH, Murray NMF, Newsom-Davis J, et al.: Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990, 40:1552\u20131556.","journal-title":"Neurology"},{"key":"10_CR19","doi-asserted-by":"crossref","unstructured":"Maddison P, Newsom-Davis J: Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2005, CD003279.","DOI":"10.1002\/14651858.CD003279.pub2"},{"key":"10_CR20","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1146::AID-MUS9>3.0.CO;2-8","volume":"20","author":"S.J. Oh","year":"1997","unstructured":"Oh SJ, Kim DS, Head TC, Claussen GC: Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1997, 20:1146\u20131152.","journal-title":"Muscle Nerve"},{"issue":"6066","key":"10_CR21","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/bmj.1.6066.946-a","volume":"1","author":"L.D. Blumhardt","year":"1977","unstructured":"Blumhardt LD, Joekes AM, Marshall J, Philalithis PE: Guanidine treatment and impaired renal function in the Eaton-Lambert syndrome [case report]. Br Med J 1977, 1(6066):946\u2013947.","journal-title":"Br Med J"},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1212\/WNL.34.10.1324","volume":"34","author":"H. Lundh","year":"1984","unstructured":"Lundh H, Nilsson O, Rosen I: Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984, 34:1324\u20131330.","journal-title":"Neurology"},{"key":"10_CR23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/WNL.31.3.265","volume":"31","author":"N.M.F. Murray","year":"1981","unstructured":"Murray NMF, Newsom-Davis J: Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981, 31:265\u2013271.","journal-title":"Neurology"},{"key":"10_CR24","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"K.M. McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA: 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989, 321:1567\u20131571.","journal-title":"N Engl J Med"},{"key":"10_CR25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","volume":"54","author":"D.B. Sanders","year":"2000","unstructured":"Sanders DB, Massey JM, Sanders LL, Edwards LJ: A randomized trial of 3,4 diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000, 54:603\u2013607.","journal-title":"Neurology"},{"key":"10_CR26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1055\/s-2008-1062260","volume":"28","author":"B. Mahadeva","year":"2008","unstructured":"Mahadeva B, Phillips LH, Juel VC: Autoimmune disorders of neuromuscular transmission. Semin Neurol 2008, 28:212\u2013227.","journal-title":"Semin Neurol"},{"key":"10_CR27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0733-8619(18)30103-8","volume":"12","author":"K.M. McEvoy","year":"1994","unstructured":"McEvoy KM: Diagnosis and treatment of Lambert-Eaton myasthenic syndrome. Neurol Clin 1994, 12:387\u2013399.","journal-title":"Neurol Clin"},{"issue":"8240","key":"10_CR28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(81)90474-8","volume":"2","author":"B. Lang","year":"1981","unstructured":"Lang B, Newsom-Davis J, Wray D, et al.: Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981, 2(8240):224\u2013226.","journal-title":"Lancet"},{"key":"10_CR29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","volume":"34","author":"J. Newsom-Davis","year":"1984","unstructured":"Newsom-Davis J, Murray NMF: Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984, 34:480\u2013485.","journal-title":"Neurology"},{"key":"10_CR30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","volume":"47","author":"P.G. Bain","year":"1996","unstructured":"Bain PG, Motomura M, Newsom-Davis J, et al.: Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996, 47:678\u2013683.","journal-title":"Neurology"},{"key":"10_CR31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1055\/s-2007-985331","volume":"27","author":"M.A. Ross","year":"2007","unstructured":"Ross MA: Intravenous immunoglobulin therapy for neuromuscular disorders. Semin Neurol 2007, 27:340\u2013346.","journal-title":"Semin Neurol"},{"key":"10_CR32","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0003-9993(23)00011-4","volume":"74","author":"E.L. Lohi","year":"1993","unstructured":"Lohi EL, Lindberg C, Andersen O: Physical training effects in myasthenia gravis. Arch Phys Med Rehabil 1993, 74:1178\u20131180.","journal-title":"Arch Phys Med Rehabil"},{"key":"10_CR33","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.apmr.2007.07.024","volume":"88","author":"E.H. Cup","year":"2007","unstructured":"Cup EH, Pieterse AJ, ten Broek-Pastoor JM, et al.: Exercise therapy and other types of physical therapy for patients with neuromuscular diseases: a systematic review. Arch Phys Med Rehabil 2007, 88:1452\u20131464.","journal-title":"Arch Phys Med Rehabil"},{"key":"10_CR34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM197908233010805","volume":"301","author":"Z. Argov","year":"1979","unstructured":"Argov Z, Mastaglia FL: Disorders of neuromuscular transmission caused by drugs. N Engl J Med 1979, 301:409\u2013413.","journal-title":"N Engl J Med"},{"key":"10_CR35","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.46.4.1143","volume":"46","author":"A.G. Smith","year":"1996","unstructured":"Smith AG, Wald J: Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. Neurology 1996, 46:1143\u20131145.","journal-title":"Neurology"},{"key":"10_CR36","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.arcped.2006.04.019","volume":"13","author":"E. Bosdure","year":"2006","unstructured":"Bosdure E, Attarian S, Mancini J, et al.: Lambert-Eaton myasthenic syndrome revealing neuroblastoma in 2 children [in French]. Arch Pediatr 2006, 13:1121\u20131124.","journal-title":"Arch Pediatr"},{"key":"10_CR37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1469-8749.1974.tb04187.x","volume":"16","author":"Y. Shapira","year":"1974","unstructured":"Shapira Y, Cividalli G, Szabo G, et al.: A myasthenic syndrome in childhood leukemia. Develop Med Child Neurol 1974, 16:668\u2013671.","journal-title":"Develop Med Child Neurol"},{"key":"10_CR38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajmg.a.20022","volume":"119A","author":"W.H. Hoffman","year":"2003","unstructured":"Hoffman WH, Helman SW, Sekul E, et al.: Lambert-Eaton myasthenic syndrome in a child with an autoimmune phenotype. Am J Med Genet A 2003, 119A:77\u201380.","journal-title":"Am J Med Genet A"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-009-0010-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-009-0010-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-009-0010-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T08:40:27Z","timestamp":1710060027000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-009-0010-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,8]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s11940-009-0010-z","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,8]]}}}